Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06717425 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT06717425 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 263 participants.
The verdict
NCT06717425, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight and how well they tolerate the study medicine.
Interventions
- DRUG Placebo
- DRUG PF-07976016
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2026-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06717425
The ClinicalTrials.gov registry entry for NCT06717425 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06717425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06717425 about?
NCT06717425 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a l...
What is the current status of trial NCT06717425?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2024-12-09. Estimated completion is 2026-01-12.
What interventions are being tested in trial NCT06717425?
The interventions under investigation include: Placebo (DRUG), PF-07976016 (DRUG).
Who is sponsoring clinical trial NCT06717425?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.